Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

Clinical trial NCT01630083 · COMPLETED

Trial details

NCT number: NCT01630083
Sponsor: Astellas Pharma Global Development, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction CLDN18.2-positive Adenocarcinoma of Esophagus CLDN18.2-positive Gastric Adenocarcinoma

Start date: 2012-07-19
Primary completion: 2019-01-31
Enrollment: 252

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.